← Back to Search

CAR T-cell Therapy

ITIL-168 for Skin Cancer (DELTA-1 Trial)

Phase 2
Waitlist Available
Research Sponsored by Instil Bio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 60 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new treatment for melanoma that uses the patient's own immune cells.

Eligible Conditions
  • Skin Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 60 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 60 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Objective response rate
Secondary study objectives
Disease Control Rate
Duration of Response
ORR as determined by investigators
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Cohort 3Experimental Treatment1 Intervention
Patients who had a best response of stable disease despite being treated with at least 4 doses of a PD-1 inhibitor in the previous line of therapy.
Group II: Cohort 2Experimental Treatment1 Intervention
Patients who were intolerant to a PD-1 inhibitor and have persistent disease after stopping PD-1 therapy.
Group III: Cohort 1Experimental Treatment1 Intervention
Patients who relapsed after or were refractory to at least 1 prior line of systemic therapy including a PD-1 inhibitor.

Find a Location

Who is running the clinical trial?

Instil BioLead Sponsor
2 Previous Clinical Trials
51 Total Patients Enrolled
Instil Study DirectorStudy DirectorInstil Bio, Inc.
2 Previous Clinical Trials
51 Total Patients Enrolled
~7 spots leftby Nov 2025